Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, Yu LM, Lowe DM, Rahman N, Petrou S, Richards D, Hood K, Patel M, Saville BR, Marion J, Holmes J, Png ME, Hayward G, Lown M, Harris V, Jani B, Hart N, Khoo S, Rutter H, Chalk J, Standing JF, Breuer J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson MI, Francis N, Thomas NPB, Evans P, van Hecke O, Koshkouei M, Coates M, Barrett S, Bateman C, Davies J, Raymundo-Wood I, Ustianowski A, Nguyen-Van-Tam J, Carson-Stevens A, Hobbs R, Little P, Butler CC. Gbinigie O, et al. Among authors: little p. BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176. BMJ Open. 2023. PMID: 37550022 Free PMC article.
Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial.
Hu XY, Oliver T, Willcox M, Simpson C, Thorne K, Trill J, Francis N, Stuart B, Thomas M, Little P, Liu JP, Griffiths G, Moore M. Hu XY, et al. Among authors: little p. Pilot Feasibility Stud. 2022 Dec 19;8(1):262. doi: 10.1186/s40814-022-01224-8. Pilot Feasibility Stud. 2022. PMID: 36536462 Free PMC article.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG, Saville BR, Marion J, Ogburn E, Allen J, Rutter H, Francis N, Thomas NPB, Evans P, Dobson M, Madden TA, Holmes J, Harris V, Png ME, Lown M, van Hecke O, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Mwandigha L, Galal U, Mort S, Jani BD, Hart ND, Ahmed H, Butler D, McKenna M, Chalk J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson M, Coates M, Barrett S, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Carson-Stevens A, Yu LM, Little P; PANORAMIC Trial Collaborative Group. Butler CC, et al. Among authors: little p. Lancet. 2023 Jan 28;401(10373):281-293. doi: 10.1016/S0140-6736(22)02597-1. Epub 2022 Dec 22. Lancet. 2023. PMID: 36566761 Free PMC article. Clinical Trial.
Determining the clinical and cost-effectiveness of nasal sprays and a physical activity and stress management intervention to reduce respiratory tract infections in primary care: A protocol for the 'Immune Defence' randomised controlled trial.
Vennik J, Geraghty AWA, Martinson K, Yardley L, Stuart B, Moore M, Francis N, Hay A, Verheij T, Bradbury K, Greenwell K, Dennison L, Williamson S, Denison-Day J, Ainsworth B, Raftery J, Zhu S, Butler C, Richards-Hall S, Little P. Vennik J, et al. Among authors: little p. PLoS One. 2023 Jul 14;18(7):e0285693. doi: 10.1371/journal.pone.0285693. eCollection 2023. PLoS One. 2023. PMID: 37450460 Free PMC article.
Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.
Willcox ML, Hu XY, Oliver T, Thorne K, Boxall C, He G, Simpson C, Brotherwood B, O'Neil A, Waugh R, Tilt E, Trill J, Goward N, Francis N, Thomas M, Little P, Wilkinson T, Liu JP, Griffiths G, Moore M. Willcox ML, et al. Among authors: little p. Front Pharmacol. 2023 Sep 25;14:1221905. doi: 10.3389/fphar.2023.1221905. eCollection 2023. Front Pharmacol. 2023. PMID: 37818189 Free PMC article.
Using microbiological data to improve the use of antibiotics for respiratory tract infections: A protocol for an individual patient data meta-analysis.
Boateng I, Stuart B, Becque T, Barrett B, Bostock J, Bruyndonckx R, Carr-Knox L, Ciccone EJ, Coenen S, Ebell M, Gillespie D, Hayward G, Hedin K, Hood K, Lau TMM, Little P, Merenstein D, Mulogo E, Ordóñez-Mena J, Muir P, Samuel K, Shaikh N, Tonner S, van der Velden AW, Verheij T, Wang K, Hay AD, Francis N. Boateng I, et al. Among authors: little p. PLoS One. 2023 Nov 27;18(11):e0294845. doi: 10.1371/journal.pone.0294845. eCollection 2023. PLoS One. 2023. PMID: 38011202 Free PMC article.
1,286 results